Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Arthritis, Rheumatoid 19Spondylitis, Ankylosing 6Psoriasis 4Colitis, Ulcerative 4Crohn Disease 3Inflammatory Bowel Diseases 2Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Spondylarthritis 1Sarcoidosis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammation 1Infections 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1

Interventions

Pharmaceutical Preparations 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nephrotic Syndrome × Adalimumab × Clear all
NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

University of Michigan

Phase 2 Completed
7 enrolled 12 charts
Genitourinary

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡